pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
364
stories
17d
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
raps
17d
STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
stat
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
20d
Resilience and Lilly invest $750M to boost Cincinnati drug production
biopharma dive
20d
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
20d
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
stat
21d
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
21d
Opinion: What a recent op-ed got wrong about our Covid study
stat
21d
Opinion: We once praised the American Diabetes Association’s courage. How things have changed
stat
21d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
21d
Capricor’s data clash and a fugitive in the C-suite
stat
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
22d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
22d
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
22d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
22d
FDA updates product-specific guidelines for injectable peptides
raps
22d
FDA unveils FY 2027 user fee rates
raps
22d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
23d
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
23d
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
23d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
24d
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
stat
24d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
24d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
25d
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
27d
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
27d
STAT+: Up and down the ladder: The latest comings and goings
stat
27d
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
← prev
page 3 of 13
next →
